The company's proprietary molecule, VGT-309, binds to enzymes overexpressed in tumor tissue, activating a brightly fluorescing dye that enables surgeons to identify and remove tumors during resection surgery. VGT-309 can identify multiple cancers, including lung, breast, ovarian, colorectal, and brain. Vergent's approach addresses the clinical need for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures while retaining pricing flexibility. VGT-309 is currently being evaluated for lung cancer, with potential applications for a wide range of solid tumors.